terial at the NIST, with assigned values based on isotope dilution mass spectrometry (IDMS), for use as trueness controls to verify the traceability of results from routine methods (10, 11 ) .
To date, the relationship of the MDRD Study creatinine assay to standardized creatinine was unknown, although results of smaller studies suggested the CX3 rate Jaffe assay had a small positive bias compared with an IDMS reference method (10, 11 ) . The purposes of this report are to describe procedures for calibrating the S cr assay at the Cleveland Clinic Research Laboratory (CCRL) where the MDRD Study samples were measured and to reexpress the 4-variable (modified) MDRD Study equation (6 ) for use with standardized S cr .
Materials and Methods study design
Chronic Kidney Disease Epidemiology Collaboration is a research group sponsored by the National Institute of Diabetes, Digestive and Kidney Diseases to develop and validate improved estimating equations for GFR by pooling data from research studies and clinical populations. Pooling data requires calibration of S cr assays of collaborating laboratories to creatinine assays currently used at the CCRL. The reference standard method for measurement of S cr , IDMS, is extremely labor intensive, allowing assay of only very few samples. Therefore, we followed recommendations to establish a calibration hierarchy (12 ) . The hierarchy starts with a primary calibrator that materializes the SI units used for expression of creatinine measurements, i.e., the NIST SRM 914a. This primary calibrator is used to directly calibrate the gas chromatography and liquid chromatography (LC) IDMS reference methods. From that point on, all subsequent calibrations or validations of the calibration status of lower-order methods are done via split-sample comparisons at CCRL (Fig. 1) . First, CAP Creatinine Accuracy Calibration Verification/Linearity Survey LN24 (LN24) samples were used as trueness controls to verify that the calibration of the Roche enzymatic method was traceable to LC-IDMS and correctly implemented in the CCRL. Second, values measured with the Roche enzymatic assay on a calibration panel of 40 native pooled sera prepared by the CCRL were compared with values assigned using the Beckman CX3 assay, the assay that was used during the MDRD Study and is currently in use in the CCRL. Third, with frozen samples from the MDRD Study, the Beckman CX3 assay was adjusted for drift over the past decade. The study was approved by the institutional review boards of all participating institutions.
reference samples from cap CAP 2004 LN24 samples 01 through 07 were prepared from a female-only donor pool, so the creatinine value would be slightly lower than a mixed-sex pool (10, 11, 13 ) . Sample 02 is the base female serum pool. Sample 07 had reagent-grade creatinine added to bring the creatinine to ϳ352 mol/L (4 mg/dL). Samples 03 through 06 were prepared by gravimetric admixing of samples 02 and 07. Sample 01 was prepared from sample 02 by gravimetric dilution with 0.01 mol/L phosphate buffered saline [prepared by adding one packet of Sigma P-3813 phosphatebuffered saline, pH 7.4, to 1 L of deionized water (personal communication, Mary Zimmer, January 22, 2007) ].
Creatinine concentrations in samples LN24-02 and LN24-07 were value-assigned by the NIST using an LC-IDMS method. NIST-assigned values for samples 02 and 07 were 65.032 and 353.32 mol/L (0.7390 and 4.0150 mg/dL), respectively. The creatinine values in the other pools were computed based on the known admixtures.
calibration panel
We developed a calibration panel of pooled human sera to establish the calibration relationship between the CX3 (2004) and Roche enzymatic methods across the range of S cr for use in patient samples. The calibration panel was developed at the CCRL from pooled patient sera from the Cleveland Clinic. The calibration panel included 40 reference sera (20 aliquots of 1.0 mL each frozen at Ϫ70°C) pooled from at least 10 mixed-sex donors known to have S cr values covering the full range of 177 to 442 mol/L (0.5 to 5.0 mg/dL).
Briefly, serum pools were constructed by combining within 2 h of collection excess clear serum obtained from apparently healthy patients and patients with CKD as soon as routine testing was completed. Sera were refrigerated and combined according to the creatinine concentration to achieve a final pool volume of Ն25 mL. The pools were mixed by gentle inversion and filtered; their combined creatinine concentrations were measured, and then serum was apportioned into separate 1.0 mL aliquots and frozen at Ϫ70°C. A set of 20 aliquots was thawed and analyzed in triplicate in 3 separate runs on the same day. This process was repeated on a 2nd set of 20 aliquots on a subsequent day. Each sample was analyzed with the Roche enzymatic and CX3 assays after verification that the methods were and remained within internal quality control limits. The runs also included a CAP sample C-02 from the 2003 C mailing (11 ) prepared according to Clinical and Laboratory Standards Institute 37A (14 ) as a validated reference material for each 20 pooled specimens. Runs were deemed acceptable if the concentration value for this material remained within 1 SD of the peer method mean.
Assigned values for the calibration panel were based on the Roche enzymatic assay. This method was selected because it is free from most interferences and its calibration is traceable to IDMS (15 ) . In addition, as shown later, this method was verified to recover values assigned by NIST to the CAP trueness controls.
stored samples from the mdrd study CAP proficiency test results (n ϭ 25, 2004 C01 to 2005 C10) for these 2 methods at the CCRL demonstrated a mean percentage bias to the peer method target mean of 1.01% (range, 3.46%-5.11%) and 1.79% (range, 2.09%-9.49%) for the Modular P and CX3, respectively. All results were within acceptance criteria. The range of creatinine values for these challenges was 61.9 to 663 mol/L (0.7 to 7.5 mg/dL).
computations
The mean values of repeated measurements were used for all computations. Linear regression slopes and intercepts were obtained for each comparison of assays. Intercepts that were very small and nonsignificant (P Ͼ0.05) were dropped from the regression. The final calibration relationship was obtained by combining point estimates for slopes and intercepts into a single new equation. The final creatinine calibration factor was rounded to 2 significant digits. The SE for the final calibration factor was computed with the delta method (16 ) . Ordinary least-squares regressions were used instead of errors-in-variables regressions because correlations were Ͼ0.993. These extremely high correlations indicated the measurement error variance was a very small fraction of the total variance in this calibration setting, at which samples spanned a wide range of creatinine values and assays were averaged across repeated measurements. The final creatinine calibration factor was then incorporated into the constant in the MDRD Study GFR estimating equation.
Results

standardization of s cr assays
Use of CAP sample for verification of traceability of Roche enzymatic assay to IDMS. Results of assays of the LN24 (Fig. 3) . The regression of the Roche enzymatic on the Beckman Synchron CX3 method showed a slope (SE) of 0.915 (0.009) and intercept of Ϫ2.30 (Fig. 4) computation of the idms-traceable calibration factors and reexpression of the mdrd study equation
The general method for calibrating the CCRL assays to the IDMS assay at NIST is given in Table 2 , equation 1. For all 3 comparisons, intercepts for the regression were taken to be zero, so the final calibration was derived by multiplication of regression slopes (1.0 ⅐ 0.906 ⅐ 1.046 ϭ 0.95; Fig.  1 ). The SE of this correction factor, calculated with the delta method and assuming the Roche enzymatic method to be equivalent to the gold standard method, was 0.005. The published MDRD Study equation ( 
Discussion
Variability among clinical laboratories in calibration of S cr assays is an important limitation in the use of GFR estimating equations. Variation in calibration introduces error in GFR estimates, especially at high GFRs (17 ) , and may account in part for the recent reports of widely varying performance of the MDRD Study equation in populations with higher GFRs (18 -38 ) . In particular, the bias at high GFR levels appears greater among studies in which the S cr assay was not calibrated (18 ) . This source of error can be overcome by recalibration of the clinical laboratory creatinine assay to the creatinine assay values of the research laboratory in which the estimating equation was developed. Calibration of clinical laboratory assay values obtained at a specific research laboratory is not practical for widespread implementation of reporting GFR estimates, however. The National Kidney Disease Education Program (NKDEP) has initiated a creatinine standardization program to improve and normalize S cr results used in estimating equations (8 ) . After creatinine reference materials that are traceable to higher order reference standards are developed, a proficiency testing system will be used to enable ongoing monitoring of calibration among clinical laboratories. This process is expected to be completed by 2008. Reexpression of the MDRD Study equation based on standardized assays will enable implementation of reporting estimated GFR in clinical practice using calibrated S cr assays, thereby overcoming this limitation to the current use of GFR estimating equations. Using the 2004 CAP LN24-A survey samples, we found the Roche enzymatic assay is comparable to IDMS across a range of S cr values from ϳ0.5 to 4.0 mg/dL. Note that CAP LN24 survey samples were used as recommended for trueness control, validating the Roche assay, rather than as calibration materials (8 ) . Using the CCRL calibration panel and adjusting the Beckman CX3 assay for drift since the MDRD Study, we calibrated the S cr assay at the MDRD Study laboratory and reexpressed the 4-variable MDRD Study equation for use with creatinine methods traceable to an IDMS reference measurement procedure (8 ) .
Based on the Roche method's performance in the CAP LN24, creatinine results from the Roche enzymatic method were considered to be traceable to IDMS values. These results have consistently showed the Roche enzymatic method to give results in agreement with IDMS target values. The LN24 samples were verified by the NKDEP Laboratory Working Group to have results that were commutable with those for native clinical samples for the Roche enzymatic creatinine method (personal communication, Greg Miller, December 12, 2006) . From a practical perspective, the CAP LN24 is the only material currently available for use as a trueness control and is reasonable to use for a clinical laboratory verification.
These methods may not fully account for measurement error. Our study design includes a 2-step approach to IDMS-traceable calibration of the MDRD Study samples, using combined results from 2 regressions based on split samples rather than results of a single regression based on reassay of original MDRD Study specimens on the Roche enzymatic assay. Nonetheless, our approach is robust. First, the CCRL calibration panel was prepared with rigorous techniques, and the MDRD Study stored samples were collected at the same time as the samples used to develop the equation. Second, several factors make multiplication of the regression slopes a maximum likelihood estimator with high efficiency. The 2 regressions have extremely high correlations (r 2 ϭ 0.987 and 0.994), making the loss of efficiency very small. These extremely high correlations over a wide range of creatinine show the linear relationship between the different assays. The SEs for all comparisons performed in this study were minute. Omission of the intercepts is justified by their small magnitude and absence of a statistically or clinically meaningful effect on GFR estimates in sensitivity analyses. The final IDMS-traceable calibration factor of 0.95, relating original MDRD Study S cr measures to standardized creatinine, is our best approximation. Regardless of study design, storage effects on specimens are possible, but the small difference between results on thawed MDRD Study specimens assayed a decade later and CAP samples assayed a year later suggests that any storage effects are small.
The 2003 CAP survey of 5624 clinical laboratories, using a fresh-frozen serum reference material with an assigned value of 79.38 mol/L (0.902 mg/dL) by IDMS, showed a range of method-dependent bias across laboratories from an underestimate of 5.28 mol/L (0.06 mg/ dL) to an overestimate of 27.28 mol/L (0.31 mg/dL) (10 ) . This finding suggests that in many laboratories, standardization of S cr assays will lead to decreased reported S cr concentrations, requiring redefinition of the reference range. Without reexpression of estimating equations, lower reported values for S cr would increase GFR estimates. Reexpression of the MDRD Study equation according to the standardized assay enables consistent interpretation of estimated GFR by use of this equation. Use of other GFR estimating equations will require reexpression of the equations with standardized S cr . The effect of standardization of S cr assays on urine creatinine results has not been studied. Thus, it is not possible at this time to determine the effect of standardization on measurements and estimates of creatinine clearance.
Creatinine calibration is only 1 limitation of the current estimating equations. Despite calibration, performance of the MDRD Study equation in populations with higher GFRs appears worse than in populations with lower GFRs. Possible reasons for decreased accuracy include reduced creatinine generation attributable to loss of muscle mass or decreased protein intake, especially in elderly and chronically ill persons, greater measurement error and biological variation in GFR at higher GFR levels, and limitations of generalizing equations developed in populations with CKD to populations without CKD (38 ) . The Chronic Kidney Disease Epidemiology Collaboration is addressing these issues by use of pooled analysis of individual patient data and IDMS-traceable calibration of stored specimens by standardized methods.
NKDEP currently suggests that laboratories should report estimated GFR using the original 4-variable MDRD Study equation (Table 2, Clinical Chemistry 53, No. 4, 2007 
